Stock TTNP TITAN PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Insiders Titan Pharmaceuticals, Inc.

Equities

TTNP

US8883147055

Market Closed - Nasdaq
Other stock markets
 15:47:45 2024-06-25 EDT 		5-day change 1st Jan Change
6.525 USD -1.14% Intraday chart for Titan Pharmaceuticals, Inc. -6.52% -20.91%
05-15 Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-01 Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Insiders

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024
CI
Titan Pharmaceuticals, Inc. Announces Board Changes
CI
Titan Pharmaceuticals Appoints New Chairman of the Board
MT
Titan Pharmaceuticals, Inc. Announces Board Resignations
CI
Titan Pharmaceuticals, Inc. Announces Board Changes
CI
Insider Sell: Titan Pharmaceuticals
MT
Titan Pharmaceuticals, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective August 16, 2022
CI
Titan Pharmaceuticals Appoints David E. Lazar Interim Chairman, CEO; Expands Board After Election of Director Nominees
MT
Titan Pharmaceuticals Announces Executive Changes
CI
Titan Pharmaceuticals Announces Board Expansion and Management Changes
CI
Insider Buy: Titan Pharmaceuticals
MT
Titan Pharmaceuticals, Inc. Announces Executive Changes
CI
Titan Pharmaceuticals, Inc. Announces Executive Changes
CI
Titan Pharmaceuticals, Inc. Announces Departure of Dane Hallberg, Chief Commercial Officer
CI
Titan Pharmaceuticals Appoints Dr. Kate DeVarney to Its Board of Directors
CI
Titan Pharmaceuticals, Inc. Announces European Commission ("Ec") Approves Sixmo®-Buprenorphine, the Brand Name for Probuphine®
CI
Titan Pharmaceuticals, Inc. Announces Appointment of Two Executives
CI
Titan Pharmaceuticals, Inc. Announces the Appointment of Dane D. Hallberg as Executive Vice President and Chief Commercial Officer
CI
Titan Pharmaceuticals, Inc. Appoints Federico Seghi Recli to its Board of Directors
CI
Titan Pharmaceuticals, Inc. Announces Retirement of Eurelio Cavalier from its Board
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TTNP Stock
  4. News Titan Pharmaceuticals, Inc.
  5. Insiders